In this context, a recent study based on a nation-wide cohort in the Netherlands allowed a comparison of the outcomes of all resected high-risk stage III melanoma patients treated with first-line BRAF/MEK inhibitors and anti-PD1, including 225 patients treated with BRAF/MEK inhibitors and 729 treated with anti-PD1 [62]. The gene discussed is BRAF; the disease is melanoma.